TELA Bio to Participate in Canaccord Genuity’s 41st Annual Growth Conference
August 03 2021 - 07:00AM
TELA Bio, Inc. ("TELA"), a commercial-stage medical technology
company focused on designing, developing, and marketing innovative
tissue reinforcement materials to address unmet needs in soft
tissue reconstruction, today announced that the Company will
participate in Canaccord Genuity’s 41st Annual Growth Conference.
TELA Bio's management is scheduled to present at Canaccord
Genuity’s 41st Annual Growth Conference on Thursday, August 12,
2021 at 2:00 PM EDT. Interested parties can access the live and
archived webcast at ir.telabio.com.
About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:
TELA) is a commercial-stage medical technology company focused on
designing, developing, and marketing innovative tissue
reinforcement materials to address unmet needs in soft tissue
reconstruction. The Company is committed to providing patients with
advanced, economically effective biologic material repair solutions
to minimize long-term exposure to permanent synthetic materials and
improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS
Reinforced Tissue Matrix products are purposefully designed to
address the shortcomings of existing reinforcement materials in
hernia repair, abdominal wall reconstruction, and plastic and
reconstructive surgery. For more information, visit
www.telabio.com.
Investor ContactGreg
Chodaczek347-620-7010 ir@telabio.com
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Feb 2024 to Mar 2024
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Mar 2023 to Mar 2024